The abstract is read at the publisher; the summary is JClub's.
A high-throughput Caco-2 platform identified 33 new bacteria–drug pairs where bacterial biotransformation products show different epithelial permeability than the corresponding drugs.
- Why it matters: Drug pharmacokinetics varies because microbial metabolism and epithelial transport both shape small-molecule absorption, but scalable ways to measure permeability effects are limited.
- What they did: The workflow combined anaerobic bacterial cultures or ex vivo microbiota with Caco-2 monolayers and a marker panel, testing 482 drugs and 259 bacterially produced metabolites.
- The result: Untargeted metabolomics detected 397 bacterially produced metabolites, with more than 79% not crossing the monolayer, and the system also matched known biotransformations and expected absorption profiles.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.